Suppr超能文献

隐匿性IIIA-N2期患者接受初始手术后总体生存率良好。

Occult stage IIIA-N2 patients have excellent overall survival with initial surgery.

作者信息

Kim Min P, Correa Arlene M, Hofstetter Wayne L, Mehran Reza J, Rice David C, Roth Jack A, Vaporciyan Ara A, Walsh Garrett L, Erasmus Jeremy J, Swisher Stephen G

机构信息

Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Division of Thoracic Surgery, Department of Surgery, Houston Methodist, Houston, Texas, USA.

出版信息

J Thorac Dis. 2018 Dec;10(12):6670-6676. doi: 10.21037/jtd.2018.10.94.

Abstract

BACKGROUND

Patients may be found to have stage IIIA-N2 at the final pathology after the initial surgery. We want to determine the survival rate in this unique group of patients.

METHODS

We reviewed all patients who underwent surgical resection for lung cancer from 2000 to 2011 who had pathologic stage N2 without induction therapy. We determined the clinicopathologic characteristics and survival rate in this unique group of patients.

RESULTS

A total of 101 patients met the inclusion criteria. The average age of the group was 65 years old with 53 (53%) females. The chest computed tomography (CT) scans showed 30 patients (30%) with mediastinal lymphadenopathy (>1 cm) and 13 (13%) with multistation disease. The positron emission tomography-computed tomography (PET-CT) showed 24 patients (24%) with N2 positive uptake. Invasive mediastinal staging prior to surgery occurred in 43 patients (43%). Eighty-four patients underwent a lobectomy (83%), 7 with bilobectomy (7%), and 10 with pneumonectomy (10%). The most common pathology was adenocarcinoma with 73 patients (72%) and the second most common was squamous cell carcinoma with 22 patients (22%). Most of the patients completed the adjuvant chemoradiation therapy (86%). The 5-year survival rate was 48% and the 10-year survival rate was 24%.

CONCLUSIONS

Pathologic stage IIIA-N2 non-small cell lung cancer (NSCLC) is a heterogeneous disease process with a very small group of patients undergoing initial surgery. Patients with occult stage IIIA-N2 who undergo initial surgery have an excellent overall survival rate.

摘要

背景

患者在初次手术后的最终病理检查中可能被发现处于IIIA-N2期。我们想要确定这一独特患者群体的生存率。

方法

我们回顾了2000年至2011年期间接受肺癌手术切除且病理分期为N2期且未接受诱导治疗的所有患者。我们确定了这一独特患者群体的临床病理特征和生存率。

结果

共有101例患者符合纳入标准。该组患者的平均年龄为65岁,其中女性53例(53%)。胸部计算机断层扫描(CT)显示30例患者(30%)有纵隔淋巴结肿大(>1 cm),13例(13%)有多站病变。正电子发射断层扫描-计算机断层扫描(PET-CT)显示24例患者(24%)N2摄取阳性。43例患者(43%)在手术前行有创纵隔分期。84例患者接受了肺叶切除术(83%),7例接受了双肺叶切除术(7%),10例接受了全肺切除术(10%)。最常见的病理类型是腺癌,有73例患者(72%),第二常见的是鳞状细胞癌,有22例患者(占22%)。大多数患者完成了辅助放化疗(86%)。5年生存率为48%,10年生存率为24%。

结论

病理IIIA-N2期非小细胞肺癌(NSCLC)是一种异质性疾病过程,仅有一小部分患者接受初次手术。接受初次手术的隐匿性IIIA-N2期患者总体生存率良好。

相似文献

引用本文的文献

1
Long-term outcomes of surgery in resectable single-station N2 non-small cell lung cancer patients.可切除的单站N2期非小细胞肺癌患者手术的长期预后
Turk Gogus Kalp Damar Cerrahisi Derg. 2025 Mar 26;33(2):205-216. doi: 10.5606/tgkdc.dergisi.2025.27229. eCollection 2025 Apr.

本文引用的文献

1
Management of stage IIIA (N2) non-small cell lung cancer: A transatlantic perspective.ⅢA期(N2)非小细胞肺癌的治疗:跨大西洋视角
J Thorac Cardiovasc Surg. 2016 May;151(5):1235-8. doi: 10.1016/j.jtcvs.2016.01.035. Epub 2016 Mar 17.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验